信達生物(01801.HK)IBI310聯合治療三期臨床研究完成首例患者給藥
信達生物(01801.HK)公布,旗下抗CTLA-4單克隆抗體產品IBI310,聯合公司與禮來製藥(LLY.US)合作研發的的信迪利單抗注射液PD-1抑制劑「達伯舒」,用於治療一線晚期肝細胞癌的第三期關鍵臨床研究已完成首例患者入組及給藥。
該研究在中國開展,用以評估IBI310聯合達伯舒用於一線晚期肝細胞癌的有效性和安全性。信達生物醫學科學與戰略腫瘤部副總裁周輝表示,CTLA-4是一個重要的免疫抑制性受體,前期臨床研究結果顯示IBI310聯合達伯舒具有良好的安全性和抗腫瘤活性,提示聯合療法腫瘤治療中的潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.